RXRXRecursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) sells AI-driven drug discovery platforms and therapeutic candidates for oncology and neuroscience. The next catalyst is Nov 4, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to meet revenue guidance and deliver clarity on its partnership pipeline.
- Recursion’s revenue grew 26.9% YoY to $38.54M in the second quarter of 2026, but net income remains deeply negative at -$582.66M.
- Free cash flow is a drag, with -$813.03M over the last 12 months, and the company is still burning through its $1.13B equity base.
- The stock is trading at a steep discount to peers, with no clear catalysts in sight beyond the earnings report.
The Read
1% after missing Q4 2025 revenue guidance and lacking strong catalysts, then rebounded 3.
The schedule
- Wed4Nov
This earnings report will test the company's ability to meet guidance and deliver on its pipeline progress, particularly in light of recent clinical trial updates and regulatory filings.
- Tue9Feb
This report will test the company's ability to maintain momentum from the Q3 earnings and provide clarity on its long-term strategy and financial health.
- Tue11May
This report will be a critical test of the company's ability to deliver on its long-term growth strategy and maintain investor confidence.
- Wed4Aug
This report will be a critical test of the company's ability to deliver on its long-term growth strategy and maintain investor confidence.
Past
- Wed5Aug
Actual outcome: Mixed · $3.22 at outcome
Recursion Pharmaceuticals missed Q2 earnings estimates but provided positive updates on its partnership with Genentech, advancing a neuroscience target into early discovery. The company also lowered its 2026 cash operating expense guidance, which supported the stock's rise despite the earnings miss.
Recursion Pharmaceuticals reports Q2 2026 financial results and provides operational updates.
- Fri27Feb
Actual outcome: Bear · $3.54 at outcome
Price reached or fell below bear floor ($3.20) at outcome date.
